These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23909960)

  • 21. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
    Dill PE; De Bernardis G; Weber P; Lösch U
    Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
    Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
    JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].
    Valerón-Almazán P; Vitiello M; Abuchar A; Kerdel FA
    Actas Dermosifiliogr; 2012 Mar; 103(2):165-6. PubMed ID: 21861956
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition of Angiofibromas in a Tuberous Sclerosis Patient Using Topical Timolol 0.5% Gel.
    Krakowski AC; Nguyen TA
    Pediatrics; 2015 Sep; 136(3):e709-13. PubMed ID: 26304829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
    Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
    Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.
    Koenig MK; Hebert AA; Roberson J; Samuels J; Slopis J; Woerner A; Northrup H
    Drugs R D; 2012 Sep; 12(3):121-6. PubMed ID: 22934754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].
    Cuevas Asencio I; Albornoz López R; Salido Vallejo R; Reyes Malia M
    Farm Hosp; 2012; 36(5):433-4. PubMed ID: 22858090
    [No Abstract]   [Full Text] [Related]  

  • 29. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
    Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
    Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted topical and combination laser surgery for the treatment of angiofibromas.
    Bae-Harboe YS; Geronemus RG
    Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
    Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
    J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
    Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
    Leducq S; Giraudeau B; Tavernier E; Maruani A
    J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
    Dao DD; Pixley JN; Akkurt ZM; Feldman SR
    Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas.
    Bouguéon G; Lagarce F; Martin L; Pailhoriès H; Bastiat G; Vrignaud S
    Int J Pharm; 2016 Jul; 509(1-2):279-284. PubMed ID: 27260135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
    Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD
    Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Facial angiofibromas treated by rapamycin 0.05% ointment and a combined laser therapy.
    Negosanti F; Tengattini V; Gurioli C; Neri I
    J Cosmet Dermatol; 2018 Oct; 17(5):762-765. PubMed ID: 30123982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
    DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
    Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas.
    Le Guyader G; Vieillard V; Andrieux K; Rollo M; Thirion O; Wolkenstein P; Paul M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e48-e52. PubMed ID: 32296505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful topical rapamycin treatment for facial angiofibromata in two children.
    Pynn EV; Collins J; Hunasehally PR; Hughes J
    Pediatr Dermatol; 2015; 32(3):e120-3. PubMed ID: 25790347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.